US Medical Devices Ishares ETF (IHI)

Baxter International has significantly underperformed the broader market over the past year, although analysts remain neutral amid improving fundamentals and recovery prospects.

Boston Scientific underperformed the broader market, though analysts remain optimistic, citing strong earnings execution, innovation, and meaningful upside from current levels.

J&J’s Ottava clearance knocked Intuitive's shares lower, but recurring revenue and surgeon switching costs suggest the market overreacted.

It’s time to start looking at the other 10 sectors of the S&P 500 to see what looks most likely to pick up the slack if and when the artificial intelligence (AI) trade finally loses steam.

Over the long term, the IHI ETF looks like a good turnaround story.

STERIS has underperformed the broader market over the past year, but analysts are cautiously optimistic about the stock’s prospects.

Although Insulet has lagged the broader market over the past year, Wall Street analysts remain strongly optimistic about the company’s long-term growth prospects.

Go beyond the broad index and find which segment of healthcare best suits your portfolio needs now.

Stryker stock has underperformed the broader market over the past year, but analysts remain highly bullish about its prospects.

While GE HealthCare Technologies has notably underperformed the S&P 500 over the past 52 weeks, Wall Street analysts maintain a moderately optimistic outlook about the stock’s prospects.